Abstract
Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Current Cancer Drug Targets
Title: Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
Volume: 9 Issue: 6
Author(s): Debmalya Barh, Anil Kumar, Suvro Chatterjee and Triantafillos Liloglou
Affiliation:
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Abstract: Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Export Options
About this article
Cite this article as:
Barh Debmalya, Kumar Anil, Chatterjee Suvro and Liloglou Triantafillos, Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271549
DOI https://dx.doi.org/10.2174/156800909789271549 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Formulation and Evaluation of pH Sensitive Sustained Release Hydrogel of Methotrexate
Clinical Cancer Drugs Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression
Current Cancer Drug Targets Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Editorial [ Infectious Diseases: What is in our future? ]
Infectious Disorders - Drug Targets Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics
Current Psychiatry Reviews Perspectives in Medicinal Chemistry: Metallomics and New Targets in Metal-Based Drug Discovery
Current Topics in Medicinal Chemistry Overexpression of <i>microRNA-21</i> in the Serum of Breast Cancer Patients
MicroRNA Boron-Containing Chlorins and Tetraazaporphyrins: Synthesis and Cell Uptake of Boronated Pyropheophorbide A Derivatives
Anti-Cancer Agents in Medicinal Chemistry Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes
Anti-Cancer Agents in Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy The Role of Gender-specific Cytokine Pathways as Drug Targets and Gender- specific Biomarkers in Personalized Cancer Therapy
Current Drug Targets Facile Synthesis of Anticancer Drug NCX 4040 in Mild Conditions
Letters in Organic Chemistry Multi-Target Compounds Acting in the Central Nervous System Designed From Natural Products
Current Medicinal Chemistry Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment
Current Cancer Therapy Reviews Protein Kinase CK2 as Regulator of Cell Survival: Implications for Cancer Therapy
Current Cancer Drug Targets Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry End of Life Issues – Hong Kong, France and Canada
Current Cancer Therapy Reviews Nanoparticle Coated Viral Vectors for Gene Therapy
Current Biotechnology